TOP TIERMARKET NEWSWIRE
News & sentiment

TREVI THERAPEUTICS I (TRVI) — News & AI sentiment

TREVI THERAPEUTICS I (TRVI) news roundup. 3 stories aggregated over the last 30 days. Average 30-day sentiment is 56.7/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
0
30d stories
3
avg sentiment 56.7/100
Insider net (90d)
$0
0 buys · 0 sells
Congress (90d)
0
0 buys · 0 sells

TRVI news in the last 24 hours, 7 days, 30 days and 90 days

How much TRVI coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowTRVI storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days0—no coverage
Last 30 days356.7/100TRVI headlines →
Last 90 days2158.5/100TRVI headlines →

Latest stories on TRVI

Sep 3
Aug 26
Aug 20
Aug 16
Aug 7
Aug 7
Aug 7
Aug 7
Raymond James raises Trevi Therapeutics price target on pipeline progress
Investing.com Analyst Ratings61 · neutralanalyst
Aug 7
Aug 6
Aug 6
Aug 6
Aug 6
Aug 6
Jul 30
Jul 28
BMO initiates Trevi Therapeutics stock at Outperform, $36 target
Investing.com Analyst Ratings61 · neutralanalyst
Jul 20
Trevi Therapeutics stock price target raised to $24 by H.C. Wainwright
Investing.com Analyst Ratings61 · neutralanalyst
Jul 20
Jul 18
Jul 17
Jul 10
Jun 17
Jun 3
May 15
Open TRVI in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →